1979. Waning of humoral immunity depending on the types of COVID-19 vaccine. (15th December 2022)

• Record Type: Journal Article
• Authors: Lim, So Yun; Kim, Ji Yeon; Jung, Jiwon; Yun, Sung-Cheol; Kim, Sung-Han
• Is Part Of: Open forum infectious diseases. Volume 9:(2022)Supplement 2
• Publication Date: 2022-12-15
• Subjects: Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac492.1604
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: There are limited data on the rates of the waning of antibody levels after two-dose and booster vaccination according to the different platforms of COVID-19 vaccines. Methods: We enrolled healthcare workers (HCWs) in a tertiary care hospital who received homologous two-dose vaccination, followed by a homologous or heterologous booster mRNA vaccine. SARS-CoV-2 S1-specific IgG was measured using ELISA. A linear mixed regression model was used to compare the slope from the peak antibody titer to the lowest antibody titers 3 months after vaccination. Results: A total of 113 HCWs (BNT162b2 (n=48 [42%]), ChAdOx1 nCoV-19 (n=52 [46%]) or mRNA-1273 (n=13 [12%])) were enrolled in this prospective cohort study. More gradual antibody waning was observed over 3 months with the two-dose ChAdOx1 nCoV-19 (ChAdOx1) than with the two-dose BNT162b2 or mRNA-1273 (p< 0.001 and p=0.001, respectively). In addition, homologous mRNA-1273 booster induced a more durable antibody response than homologous BNT162b2 booster (p< 0.001) or heterologous ChAdOx1-BNT162b2 booster (p< 0.001). Conclusion: 2-dose homologous ChAdOx1 vaccination or homologous mRNA-1273 booster appears to induce more-durable antibody responses than 2-dose homologous mRNA vaccination, homologous BNT162b2 booster, or 2-dose ChAdOx1 followed by BNT162b2 booster. Disclosures: All Authors : No reported disclosures.